How to buy XORTX Therapeutics stock (XORTX Therapeutics)

XORTX Therapeutics, a company that develops therapies to inhibit the production of uric acid, has applied for listing on the Nasdaq.

Our top picks for where to buy XORTX Therapeutics stock

Buy XORTX Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

XORTX Therapeutics stock price (NASDAQ: XRTX)

Use our graph to track the performance of XRTX stocks over time.

XORTX Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-22.

Latest market close	$1.19
52-week range	$1.06 - $7.00
50-day moving average more info button	$1.58
200-day moving average more info button	$2.33
Wall St. target price	$12.17
PE ratio more info button	10.5
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$0.12

Is it a good time to buy XORTX Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

XORTX Therapeutics price performance over time

Historical closes compared with the close of $1.121 from 2024-12-26

1 week (2024-12-20)	2.84%
1 month (2024-11-27)	-7.36%
3 months (2024-09-27)	-27.68%
6 months (2024-06-27)	-41.80%

1 year (2023-12-27)	-48.58%
2 years (2022-12-27)	-98.52%
3 years (2021-12-27)	149.85
5 years (2019-12-24)	N/A

Is XORTX Therapeutics stock undervalued or overvalued?

Valuing XORTX Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of XORTX Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

XORTX Therapeutics's P/E ratio

XORTX Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, XORTX Therapeutics shares trade at around 11x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, XORTX Therapeutics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

• Biogen (BIIB.US): 13.55
• Pfizer (PFE.US): 35.65
• Johnson-and-Johnson (JNJ.US): 24.11

XORTX Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-33.14%
Return on equity TTM	-29.36%
Profit margin	0%
Book value	$2.32
Market Capitalization more info button	$4.3 million

TTM: trailing 12 months

XORTX Therapeutics share dividends

We're not expecting XORTX Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

• Pfizer (PFE.US) (6.53% forward annual dividend yield)
• Johnson-and-Johnson (JNJ.US) (3.43% forward annual dividend yield)

Have XORTX Therapeutics's shares ever split?

XORTX Therapeutics's shares were split on a 1:9 basis on 13 November 2023 . So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your XORTX Therapeutics shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for XORTX Therapeutics shares which in turn could have impacted XORTX Therapeutics's share price.

XORTX Therapeutics share price volatility

Over the last 12 months, XORTX Therapeutics's shares have ranged in value from as little as $1.06 up to $7. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while XORTX Therapeutics's is -0.207. This would suggest that XORTX Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, XORTX Therapeutics has bucked the trend.

To put XORTX Therapeutics's beta into context you can compare it against those of similar companies.

• Biogen (BIIB.US): -0.061
• Pfizer (PFE.US): 0.615
• Johnson-and-Johnson (JNJ.US): 0.518

XORTX Therapeutics overview

XORTX Therapeutics Inc. , a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada. .

Frequently asked questions

What percentage of XORTX Therapeutics is owned by insiders or institutions?
Currently 3.016% of XORTX Therapeutics shares are held by insiders and 6.032% by institutions. How many people work for XORTX Therapeutics?
Latest data suggests 2 work at XORTX Therapeutics. When does the fiscal year end for XORTX Therapeutics?
XORTX Therapeutics's fiscal year ends in December. Where is XORTX Therapeutics based?
XORTX Therapeutics's address is: 3710 ? 33rd Street NW, Alberta Beach, AB, Canada, T2L 2M1 What is XORTX Therapeutics's ISIN number?
XORTX Therapeutics's international securities identification number is: CA98420Q2071